A 48-year-old woman with metastatic colorectal cancer is being treated with a combination regimen. The oncologist adds a drug that is a thymidylate synthase inhibitor and is converted to its active form by thymidine phosphorylase. This drug is often combined with leucovorin to enhance its efficacy. Which is the drug of choice in this colorectal cancer regimen?